Related Experiment Videos
[Experimental testing of a new gastrotherapeutic agent]
Fortschritte Der Medizin
|January 22, 1976
Summary
A new gastrointestinal drug, AcT 72, containing propantheline bromide, perazine, and antacids, was found to significantly reduce gastric motility. This effect prolongs the drug
Area of Science:
- Pharmacology
- Gastroenterology
- Drug Development
Context:
- Gastrointestinal motility disorders are common.
- Gastric ulcers require effective therapeutic interventions.
- Combination therapies are explored for enhanced efficacy.
Purpose:
- To evaluate the efficacy of a novel gastrotherapeutical preparation, AcT 72.
- To assess the impact of AcT 72 on gastric motility.
- To determine the therapeutic potential of AcT 72 in gastric conditions.
Summary:
- AcT 72, a combination of propantheline bromide, perazine, and antacids, was tested in two series of experiments.
- Peroral administration of AcT 72 significantly reduced gastric motility compared to controls.
- Therapeutic doses were used, leading to a prolonged duration of action in the stomach.
Impact:
- Reduced gastric motility offers therapeutic value for patients with gastric ulcers.
- The prolonged action may allow for reduced daily dosing requirements.
- AcT 72 demonstrates potential as a novel treatment for gastrointestinal motility issues.